Publications

BibTex format

@article{Fessas:2020:10.1111/imm.13141,
author = {Fessas, P and Possamai, LA and Clark, J and Daniels, E and Gudd, C and Mullish, BH and Alexander, JL and Pinato, DJ},
doi = {10.1111/imm.13141},
journal = {Immunology},
pages = {167--177},
title = {Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.},
url = {http://dx.doi.org/10.1111/imm.13141},
volume = {159},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Immune checkpoint inhibition with monoclonal antibodies is becoming increasingly commonplace in cancer medicine, having contributed to a widening of therapeutic options across oncological indications. Disruption of immune tolerance is the key mechanism of action of checkpoint inhibitors and although immune-related adverse events are a typical class effect of these compounds, the relationship between toxicity and response is not fully understood. Awareness and vigilance are paramount in recognizing potentially life-threatening toxicities and managing them in a timely manner. In this review article, we provide an overview of the clinical features, pathological findings and management principles of common immune-related toxicities, attempting to provide mechanistic insight into an increasingly common complication of cancer therapy.
AU  - Fessas,P
AU  - Possamai,LA
AU  - Clark,J
AU  - Daniels,E
AU  - Gudd,C
AU  - Mullish,BH
AU  - Alexander,JL
AU  - Pinato,DJ
DO  - 10.1111/imm.13141
EP  - 177
PY  - 2020///
SP  - 167
TI  - Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.
T2  - Immunology
UR  - http://dx.doi.org/10.1111/imm.13141
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31646612
UR  - http://hdl.handle.net/10044/1/74226
VL  - 159
ER  -

Download

DrJamesAlexander

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)